



UNITED
A non-profit organization

Scientific
Group

CBI-2020

CANCER BIOLOGY AND IMMUNOTHERAPY CONGRESS

March 30-April 01, 2020


CME credits

approved by the Mercer Medical School

MERCER
UNIVERSITY

Journal Partner

Human Vaccines & Immunotherapeutics
(produced by Taylor & Francis)



HV&I has partnered with, and will
publish a **SPECIAL ISSUE** from,
the **CANCER BIOLOGY AND
IMMUNOTHERAPY CONFERENCE**
March 30 - April 1, 2020, Savannah, Georgia, USA

**Register and
submit to the
Special Issue**

Venue

The DeSoto Savannah
15 E Liberty, Savannah, GA 31401, USA

Nearest Airport to Reach The DeSoto Savannah Hotel is
Savannah/Hilton Head International Airport

About Cancer Biology and Immunotherapy-2020

To date, the passive immunotherapeutic approaches which have been FDA-approved clearly provide clinical benefit to a proportion of advanced disease patients. While these treatments have been heralded as much needed improvements, the nearly 600,000 Americans who died of cancer last year did not gain the level of benefit we would have hoped from modern cancer care. As the frontiers of cancer immunotherapy are pushing forward, we need to concentrate on integrative translational medicine. We are proposing to have an outlet for a comprehensive discussion, which will simultaneously integrate a deep understanding of the biology of cancer along with the development of future treatment concepts to ultimately realize the full potential of this clinical revolution.

To this end, together with the United Scientific Group (USG) and under the auspices of the Mercer Medical School, Savannah Campus is organizing a Cancer Biology and Immunotherapy (CBI) meeting in Savannah, Georgia in March 30 to April 1, 2020. USG has successfully organized five Vaccine Research and Development meetings and during these events it has become apparent the cancer vaccine and immunotherapy research portions need to be expanded to their own conference.

Janus



Janus was the Roman god of beginnings and transitions. It is depicted as a two-faced image that looks to the future and the past. As first pointed out by Dr. Olivera Finn, the Janus principle can be used to illustrate the past accomplishments and future opportunities in Immunotherapy of Cancer. In this case, immune function/tumor rejection and immune dysfunction/tumor progression. *Ann Oncol* 2012 Sep 23 (Suppl 8).

Meeting Topics

- **Cancer Pathology, Tumor Growth Kinetics**
- **Cancer Metastasis**
- **Genomic Heterogeneity**
 - Among different patients
 - Within Primary tumors
 - Among cells that metastasize
 - Within metastatic lesions
- **Passive Immunotherapy**
 - Checkpoint inhibitors
 - CAR-T
 - Tumor infiltrating lymphocytes
 - Monoclonal Antibodies
 - Laboratory and Industry production
- **Immunotherapy Beyond Checkpoint Inhibitors**
- **Host-Tumor Interactions**
- **Cancer Vaccines: Design and Medical Translation**
- **Active Specific Immunotherapy**
 - Patient selection for clinical trials: Advanced, Occult disease
 - Adjuvants, development of biocompatible delivery systems
 - Vaccine design and production technology
 - Neoproteins and neoepitopes
- **Cancer Treatment Monitoring and Drug Design**
- **Cancer Prevention**
 - Status Australian trials of HPV vaccine for Cervical Cancer



Conference Chairman

Dr. Michael G Hanna, Jr. received his PhD in experimental pathology and immunology from the Oakridge National Laboratory/University of Tennessee (TN, USA) in the 1960s. He was a consultant with NASA for the lunar receiving laboratory during Apollo 11 and 12, for which his expertise in immunology was used in the testing of the lunar core powder for immunogenic or pathogenic materials. Dr. Hanna served during 1974-83 as first Director of the Basic Research Program and from 1977 as first Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA). He was Chief Operating Officer during 1985-94 of Organon Teknika/Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, The Netherlands. He developed and obtained approvals for TICE BCG for the treatment of carcinoma in situ (CIS) bladder cancer, and for prophylaxis of recurrence of superficial bladder cancer and therapy. This treatment remains standard therapy of premetastatic bladder cancer. Subsequently, Dr. Hanna founded PerImmune Inc., for which he served as President and Chief Executive Officer. In 2007, Dr. Hanna founded Vaccinogen Inc., where he served as Chairman and CEO. Currently, Dr. Hanna is Chairman Emeritus, the company is a pioneer in the field of cancer vaccines.



*Michael G. Hanna Jr., PhD
Chairman, Organizing Committee
Cancer Biology, Immunotherapy Congress
Founder and Executive Chairman
Per-Immune Inc.*

08:30-09:00 Welcome and Introductions

Dr. Wayne C. Glasgow, Senior Vice Provost for Research, Mercer University

Dr. J. David Baxter, Senior Associate Dean Savannah, Mercer University School of Medicine

Dr. Michael G. Hanna Jr., Per-Immune Inc., Savannah, GA

Plenary Session 1: Cancer biology, pathology and metastasis

Moderator: Dr. Michael G. Hanna Jr, Per-Immune Inc., Savannah, GA

09:00-09:40 **Dr. Julie Magarian Blander**, Cornell University, New York, NY
Innate immunity in immunotherapy, macrophages and dendritic cells

09:40-10:20 **Dr. J J O'leary**, Trinity College, Dublin, Ireland
Cancer pathology and tumor growth kinetics, metastasis and tumor cell-stroma relationships

10:20-11:00 **Dr. Heyu Ni**, University of Toronto, Toronto, Canada
The roles of blood platelets in cancer: immune response, metastasis and cancer-related thrombosis

11:00-11:20 **Coffee Break**

11:20-12:00 **Dr. Michael Hwang**, Johns Hopkins Medical Institute, Baltimore, MD
Mutations in oncogenes and tumor suppressor genes drive tumorigenesis: MANA bodies
TCR-mimic antibodies for cancer therapy

12:00-12:40 **Dr. Joshua L. Hood**, University of Louisville, KY
Exploring tumor exosome induction of macrophage polarity and therapeutic potential in the context of immune suppression

12:40-01:00 **Panel Discussion**

01:00-02:00 **Lunch**

Plenary Session 2: Passive immunotherapy

Moderator: Dr. Jason David Howard, Sanofi-Genzyme, Cambridge, MA

02:00-02:40 **Dr. Jason David Howard**, Sanofi-Genzyme, Cambridge, MA
Passive immunotherapy in advanced disease cancer patients

02:40-03:20 **Dr. Christopher E. Rudd**, University of Montreal, Quebec, Canada
GSK-3 Inactivation synergizes with PD-1/PL1 and CTLA-4 blockade in cancer immunotherapy

03:20-04:00 **Dr. Keith Knutson**, Mayo Clinic, Jacksonville, FL
Immunotherapy beyond checkpoint

04:00-04:30 **Coffee Break**

04:30-05:10 **Dr. Michael Lotze**, UPMC Hillman Cancer Center, Pittsburgh, PA
Adoptive cell therapies for cancer: focus on tumor infiltrating lymphocytes



05:10-05:50 **Dr. Ugo Rovigatti**, University of Florence, Italy
From anti-GD2 passive immunotherapy in High-Risk Neuroblastoma (HR-NBL) to a new landscape of genomic aberrations and immunotherapy targets

05:50-06:30 Panel Discussion

DAY - 2 | MARCH 31
2020

CBI 2020

Plenary Session 3: Cancer immunoprevention

Moderator: Dr. Olivera Finn, University of Pittsburgh, Pittsburgh, PA

08:30-09:10 **Dr. Hideho Okada**, University of California San Francisco, CA
Vaccine approaches for patients with low-grade glioma aimed at prevention of malignant transformation

09:10-09:50 **Dr. Vincent K. Tuohy**, Cleveland Clinic, Lerner Institute, Cleveland Ohio
Primary immunoprevention of adult onset cancers

09:50-10:30 Coffee Break

10:30-11:10 **Dr. Olivera Finn**, University of Pittsburgh, Pittsburgh, PA
Vaccines for the prevention of non-viral cancers

11:10-12:00 Panel discussion

12:00-01:00 Lunch

Plenary Session 4: Active specific immunotherapy

Moderator: Dr. Robert Dillman, AIVITA Biomedical, Irvine, CA

01:00-01:40 **Dr. Robert Dillman**, AIVITA Biomedical, Irvine, CA
Evolution of therapeutic cancer vaccines

01:40-02:20 **Dr. Michael G. Hanna Jr.**, Per-Immune Inc., Savannah, GA
Unlocking The Potential of Personal Cancer Vaccines: The Clinical Ramifications of Antigen Competition Driven Immunoediting

02:20-02:50 Coffee Break

02:50-03:30 **Dr. J. Milburn Jessup**, Veterans Administration Medical Center, Washington, DC
Immunogenic cell death is an agnostic adaptive immunity primer for solid tumors

03:30-04:10 **Dr. F. Guirakhoo**, GeoVax Inc. Atlanta, GA
MVA-VLP as a safe and effective platform for delivery of multi-antigen vaccine candidates for infectious diseases and cancer

04:10-05:00 Panel Discussion

Plenary Session 5: Cancer immunotherapy monitoring, methodology and drug design

- Moderator:** Dr. Peter Nara, Keystone Bio Inc., St. Louise, MO
- 08:30-09:10 **Dr. Peter Nara**, Keystone Bio Inc., St. Louise, MO
Cancer treatment monitoring and drug design
- 09:10-09:40 **Dr. Richard G. Pestell**, Pennsylvania Cancer and Regenerative Medicine Center, PA
Cancer Stem cells (CSC). Genetic drivers and therapeutic targeting via a new receptor
- 09:40-10:10 **Dr. Martin D'Souza**, School of Pharmacy, Mercer Medical School, Atlanta, GA
Cancer nano-vaccines delivered via "Band-Aid Like" microneedle patches
- 10:10-10:30 **Coffee Break**
- 10:30-11:00 **Dr. Joanna Roder**, Biodesix, Boulder, CO
Application of machine learning to proteomic datasets: What can AI tell us about immune phenotypes from measurements of the circulating proteome?
- 11:00-11:30 **Dr. Karen A. Norris**, University of Georgia, Athens, GA
Immunity and immunization in the immunocompromised host
- 11:30-12:00 **Dr. Pavan Muttil**, The University of New Mexico, Albuquerque, NM
A pulmonary delivery approach to administer combination therapies against lung cancer: are animal models a bane or a boon?
- 12:00-12:30 Panel Discussion**
- 12:30-01:30 **Lunch and Meeting Closure**

Note: *This is a tentative program and subject to change*





UNITED
A non-profit organization

**Scientific
Group**

8105, Rasor Blvd - Suite #112,
PLANO, TX 75024, USA

Ph: +1-469-854-2280/81

Toll Free: +1-844-395-4102

Fax: +1-469-854-2278

Email: cbi@uniscigroup.org

Web: <https://immunology.unitedscientificgroup.org/>